NCT07307989 Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis
| NCT ID | NCT07307989 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Chang Gung Memorial Hospital |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2029-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 300 participants in total. It began in 2025-08-01 with a primary completion date of 2029-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be conducted at six medical institutions in Taiwan, recruiting patients who visit neurology outpatient clinics or are hospitalized within 30 days after an ischemic stroke. Participants will be randomly assigned to either the experimental group (moderate-intensity statin plus ezetimibe) or the control group (moderate- or high-intensity statin). Research assistants will screen patients aged 40 or older who have had an ischemic stroke or transient ischemic attack within 30 days, have atherosclerosis, and have LDL-C levels ≥100 mg/dL. Eligible cases will be reviewed by the attending physician. With physician approval, patients will be invited to join the study, and those who agree and sign informed consent will be enrolled.
Eligibility Criteria
Inclusion Criteria: * (1) clinical diagnosis of ischemic stroke or TIA; (2) Stroke or TIA symptoms and randomized within 30 days, then taking assigned medication within 2 days of randomization; (3) aged 20 years or older; (4) LDL-C ≥ 100 mg/dL after index ischemic stroke or TIA; (5) having evidence of atherosclerosis. Exclusion Criteria: * (1) end stage renal disease because there is no clear benefit of LDL-C lowering therapy in these patients; (2) history of statin intolerance; (3) history of ezetimibe intolerance; or (4) ALT \> 100 U/L.(5) Statins were regularly used before stroke. (6) Ezetimibe was used before stroke.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07307989 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 100 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07307989 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07307989 currently recruiting?
Yes, NCT07307989 is actively recruiting participants. Contact the research team at menglee5126@gmail.com for enrollment information.
Where is the NCT07307989 trial being conducted?
This trial is being conducted at Pozi, Taiwan.
Who is sponsoring the NCT07307989 clinical trial?
NCT07307989 is sponsored by Chang Gung Memorial Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.